TLPPF - Telix Pharma Stock: Prostate Cancer Treatments Could Lead To Increased Value

2024-06-18 13:48:58 ET

Summary

• Telix Pharmaceuticals' product revenues in full-year 2023 were $502.5 million, which was an increase of 214% from 2022 with revenues of only $160.1 million.
• TLX591 + best SOC is being used to treat patients with metastatic castration-resistant prostate cancer in the ongoing phase 3 ProstACT GLOBAL study; Interim data expected Q1 of 2025.
• TLX592 was already tested in phase 1 CUPID study for patients with prostate cancer; A phase 1/2 study for this program is expected to start in the 2nd half of 2024.
• The global prostate cancer market size is anticipated to reach $13.71 billion by 2033.

Telix Pharma Overview

Telix Pharmaceuticals Limited ( TLPPF , T LX ) has already done well to advance a diagnostic for patients with Illucix diagnostic, which was approved by the FDA to help infer patients with PSMA prostate cancer. The company's revenue has increased considerably higher in 2024 to $502.5 million because of this diagnostic. Especially, when you consider that revenue had increased by as much as 214% from 2022....

For further details see: